Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02754141 · ClinicalTrials.gov registry record · Phase 1
An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 235
- Enrollment target
NCT02754141: Completed Phase 1 study, sponsored by Bristol-Myers Squibb.
NCT02754141 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 235 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (292% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02754141, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 235 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tumor-shrinking ability of experimental medication BMS-986179 alone and when combined with Nivolumab, in patients with solid cancers that are advanced or have spread.
Primary Outcome
Number of participants with drug related adverse events (AE), drug related serious adverse events (SAE), drug related AEs Leading to discontinuation and drug related deaths
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL rHuPH20
- BIOLOGICAL BMS-986179
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 235 participants |
| Start Date | 2016-06-21 |
| Est. Completion | 2021-10-12 |
| Phase | Phase 1 |
What the finished NCT02754141 record still lists
NCT02754141 is an interventional study that assigns participants to a tested intervention. The registered 235 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (292% higher).
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT02754141 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02754141 about?
NCT02754141 is a clinical study titled "An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab". The purpose of this study is to assess the safety and tumor-shrinking ability of experimental medication BMS-986179 alone and when combined with Nivolumab, in patients with solid cancers that are advanced or have spread.
What is the current status of trial NCT02754141?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 235 participants. The study started on 2016-06-21. Estimated completion is 2021-10-12.
What interventions are being tested in trial NCT02754141?
The interventions under investigation include: Nivolumab (BIOLOGICAL), rHuPH20 (BIOLOGICAL), BMS-986179 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02754141?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02754141's enrollment target sits among peer trials
235 212th of 2000 higher than 1,789 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01524211 · 235 participants · NA
Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms
- NCT05316155 · 235 participants · Phase 1
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
- NCT05353569 · 235 participants · NA
Coherent Optical Detection of Middle Ear Disease
- NCT05390918 · 235 participants · NA
Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI